miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers
Conclusions: miR-133a and miR-135a may play an antioncogenic role in pediatric AML through the ATRA-miRNA133a/135a-CDX2 pathway. They hold promise as potentially favorable prognostic indicators and novel therapeutic targets for pediatric AML.PMID:38693824 | DOI:10.1177/15330338241248576 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - May 2, 2024 Category: Cancer & Oncology Authors: Yu-Cai Cheng Zhong Fan Cong Liang Chun-Jin Peng Yu Li Li-Na Wang Jie-Si Luo Xiao-Li Zhang Yong Liu Li-Dan Zhang Source Type: research
Acute promyelocytic leukemia with additional chromosome abnormalities in a patient positive for HIV: A case report and literature review
This report describes a 49-year-old female patient with HIV who was diagnosed with high-risk APL with a new CK translocation and presents a literature review. At diagnosis, the patient presented with typical t(15;17)(q24;q21) with additional abnormalities, including add(5)(q15), add(5)(q31), add(7)(q11.2) and add(12) (p13). The results of acute myeloid leukemia mutation analysis suggested positivity for calreticulin and lysine methyltransferase 2C genes. The patient received all-trans retinoic acid combined with arsenic trioxide and chemotherapy, with morphologically complete remission after the first cycle of chemotherapy...
Source: Oncology Letters - May 2, 2024 Category: Cancer & Oncology Authors: Xiao-Lan Li Min Li Ling-Zhi Wang Juan Tian Zi-Wei Shi Kui Song Source Type: research
Cytarabine-induced peripheral neuropathy in a young patient with acute myeloid leukemia: a case report
CONCLUSION: Although rare, even a conventional dosage of cytarabine can cause peripheral neuropathy, and routine neuromuscular examinations can help in the early diagnosis and intervention to limit further progression and reverse the course of the disease.PMID:38694396 | PMC:PMC11060256 | DOI:10.1097/MS9.0000000000001937 (Source: Annals of Medicine)
Source: Annals of Medicine - May 2, 2024 Category: Internal Medicine Authors: Kshitiz Karki Sugat Adhikari Suraj Shrestha Jenish Bhandari Bidisha Baral Aastha Baral Source Type: research
Minimal residual disease monitoring in childhood Philadelphia-positive acute lymphoblastic leukemia: prognostic significance and correlation between multiparameter flow cytometry and real-time quantitative polymerase chain reaction
Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285119. Online ahead of print.ABSTRACTNot available.PMID:38695139 | DOI:10.3324/haematol.2024.285119 (Source: Haematologica)
Source: Haematologica - May 2, 2024 Category: Hematology Authors: Jun Li Anni Lu Yangyang Gao Yang Wan Junxia Wang Jingliao Zhang Tianyuan Hu Peng Wu Xiaojuan Chen Yao Zou Yumei Chen Li Zhang Ye Guo Wenyu Yang Chengwen Li Yingchi Zhang Xiaofan Zhu Source Type: research
CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia
Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.284241. Online ahead of print.ABSTRACTNot available.PMID:38695137 | DOI:10.3324/haematol.2023.284241 (Source: Haematologica)
Source: Haematologica - May 2, 2024 Category: Hematology Authors: Xin Jin Rui Sun Zhu Li Xianwu Wang Xia Xiong Wenyi Lu Hairong Lyu Xia Xiao Yunpeng Tian Hongkai Zhang Zhihong Fang Luqiao Wang Mingfeng Zhao Source Type: research
A physiologically ‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions
AbstractDasatinib, a second-generation tyrosine kinase inhibitor, is approved for treating chronic myeloid and acute lymphoblastic leukemia. As a sensitive cytochrome P450 (CYP) 3A4 substrate and weak base with strong pH-sensitive solubility, dasatinib is susceptible to enzyme-mediated drug –drug interactions (DDIs) with CYP3A4 perpetrators and pH-dependent DDIs with acid-reducing agents. This work aimed to develop a whole-body physiologically-based pharmacokinetic (PBPK) model of dasatinib to describe and predict enzyme-mediated and pH-dependent DDIs, to evaluate the impact of stron g and moderate CYP3A4 inhibitors and ...
Source: CPT: Pharmacometrics and Systems Pharmacology - May 2, 2024 Category: Drugs & Pharmacology Authors: Christina Kovar,
Helena Leonie Hanae Loer,
Simeon R üdesheim,
Laura Maria Fuhr,
Fatima Zahra Marok,
Dominik Selzer,
Matthias Schwab,
Thorsten Lehr Tags: ARTICLE Source Type: research
Comparison of older related vs younger unrelated donors for old recipients of allogeneic hematopoietic cell transplantation with AML or MDS- a large single center analysis
The introduction of reduced-intensity conditioning regimens has made allogeneic hematopoietic cell transplantation (alloHSCT) feasible for elderly recipients, aged well into their 70s1. In particular, myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), which are conventionally diseases of the elderly (median age at diagnosis ∼ 68 years for AML and ∼70 years for MDS), have become the most common disease indications for alloHCT, comprising 65-70% of all alloHCTs performed worldwide. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 2, 2024 Category: Hematology Authors: Haesook T. Kim, Vincent T Ho, Sarah Nikiforow, Corey Cutler, John Koreth, Roman M Shapiro, Mahasweta Gooptu, Rizwan Romee, Catherine J. Wu, Joseph H. Antin, Jerome Ritz, Robert J Soiffer Source Type: research
[PERSPECTIVES] Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are metabolic enzymes that interconvert isocitrate and 2-oxoglutarate (2OG). Gain-of-function mutations in IDH1 and IDH2 occur in a number of cancers, including acute myeloid leukemia, glioma, cholangiocarcinoma, and chondrosarcoma. These mutations cripple the wild-type activity of IDH and cause the enzymes to catalyze a partial reverse reaction in which 2OG is reduced but not carboxylated, resulting in production of the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG). (R)-2HG accumulation in IDH-mutant tumors results in profound dysregulation of cellular metabolism. The most...
Source: Cold Spring Harbor perspectives in medicine - May 2, 2024 Category: Research Authors: Gunn, K., Losman, J.-A. Tags: Cancer Metabolism: Historical Landmarks, New Concepts, and Opportunities PERSPECTIVES Source Type: research
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients
Blood Cancer Journal, Published online: 02 May 2024; doi:10.1038/s41408-024-01060-4Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - May 2, 2024 Category: Hematology Authors: Ann-Kristin Schm älter Maud Ngoya Jacques-Emmanuel Galimard Ali Bazarbachi J ürgen Finke Nicolaus Kr öger Martin Bornh äuser Matthias Stelljes Friedrich St ölzel Johanna Tischer Thomas Schroeder Peter Dreger Igor-Wolfgang Blau Bipin Savani Sebastian Source Type: research
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Opinion statementThe internal tandem duplication (ITD) mutation of the FMS-like receptor tyrosine kinase 3 (FLT3-ITD) is the most common mutation observed in approximately 30% of acute myeloid leukemia (AML) patients. It represents poor prognosis due to continuous activation of downstream growth-promoting signaling pathways such as STAT5 and PI3K/AKT. Hence, FLT3 is considered an attractive druggable target; selective small FLT3 inhibitors (FLT3Is), such as midostaurin and quizartinib, have been clinically approved. However, patients possess generally poor remission rates and acquired resistance when FLT3I used alone. Vari...
Source: Current Treatment Options in Oncology - May 2, 2024 Category: Cancer & Oncology Source Type: research
Benzoyl Peroxide Use in Acne Therapy: Evaluating the Association with Acute Myeloid Leukemia Risk
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - May 2, 2024 Category: Dermatology Authors: Jesse Veenstra, David Ozog Source Type: research
Evolution of natural killer cell-targeted therapy for acute myeloid leukemia
Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778-0. Online ahead of print.ABSTRACTIn hematologic oncology, acute myeloid leukemia (AML) presents a significant challenge due to its complex genetic landscape and resistance to conventional therapies. Despite advances in treatment, including intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), the prognosis for many patients with AML remains poor. Recently, immunotherapy has emerged as a promising approach to improve outcomes by augmenting existing treatments. Natural killer (NK) cells, a subset of innate lymphoid cells, have garnered attention fo...
Source: International Journal of Hematology - May 1, 2024 Category: Hematology Authors: Yuta Kaito Yoichi Imai Source Type: research
Evolution of natural killer cell-targeted therapy for acute myeloid leukemia
Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778-0. Online ahead of print.ABSTRACTIn hematologic oncology, acute myeloid leukemia (AML) presents a significant challenge due to its complex genetic landscape and resistance to conventional therapies. Despite advances in treatment, including intensive chemotherapy and hematopoietic stem cell transplantation (HSCT), the prognosis for many patients with AML remains poor. Recently, immunotherapy has emerged as a promising approach to improve outcomes by augmenting existing treatments. Natural killer (NK) cells, a subset of innate lymphoid cells, have garnered attention fo...
Source: International Journal of Hematology - May 1, 2024 Category: Hematology Authors: Yuta Kaito Yoichi Imai Source Type: research
Correlation between HOX11 Gene Expression and Clinical Prognosis of Patients with Acute Leukemia
CONCLUSION: The study suggests the potential of using HOX11 expression as a marker in clinical practice for monitoring acute leukemia prognosis.PMID:38687853 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - April 30, 2024 Category: Complementary Medicine Authors: Ling Li Jie Ma Shuzhen Shen Source Type: research
Clinical features of immature leukemias in children
Int J Hematol. 2024 Apr 30. doi: 10.1007/s12185-024-03771-7. Online ahead of print.ABSTRACTEarly T-cell precursor acute lymphoblastic leukemia (ETP-ALL), mixed phenotypic acute leukemia (MPAL), and acute myeloid leukemia with minimal differentiation (AML-M0) all originate from immature hematopoietic progenitor cells and have a poor prognosis. We investigated the clinical characteristics of these immature leukemias in 17 children (ETP-ALL: 8, MPAL: 5, AML-M0: 4) at seven institutions. Clinical and laboratory findings were comparable across disease types. Eleven and six patients received ALL- and AML-oriented induction chemo...
Source: International Journal of Hematology - April 30, 2024 Category: Hematology Authors: Daichi Sajiki Nao Yoshida Hideki Muramatsu Kimiyoshi Sakaguchi Naoko Maeda Norifumi Yokoyama Yuji Miyajima Makito Tanaka Yoshiyuki Takahashi Asahito Hama Source Type: research
